Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...

The TACTI-004 trial evaluates eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. When will the TACTI-004 trial poster be presented? The poster ...

The poster will be presented at the European Lung ... in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy ...

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell carcinoma (RCC ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

The landscape of therapeutic development is being radically reshaped by rapid technological advancements. This event will provide a unique platform to explore how both established pharmaceutical ...